Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru

Alvaro Schwalb; Rodrigo Cachay; Ericka Meza; Tatiana Cáceres; Amondrea Blackman; Fernanda Maruri; Timothy R. Sterling; Eduardo Gotuzzo

doi:10.1186/s13104-021-05832-0

Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru

Alvaro Schwalb
, Rodrigo Cachay
, Ericka Meza
, Tatiana Cáceres
, Amondrea Blackman
, Fernanda Maruri
, Timothy R. Sterling
, Eduardo Gotuzzo

Unidad de Investigación en Tuberculosis e Infecciones Respiratorias

Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical Alexander von Humboldt
Vanderbilt University Medical Center

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Objective: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. Results: There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.

Original language	English
Article number	413
Journal	BMC Research Notes
Volume	14
Issue number	1
DOIs	https://doi.org/10.1186/s13104-021-05832-0
State	Published - Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Drug resistance
Levofloxacin
Moxifloxacin
Ofloxacin

Access to Document

10.1186/s13104-021-05832-0

Cite this

@article{ea8b243fb2be4d94a81e669328de6efb,

title = "Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru",

abstract = "Objective: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. Results: There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95\% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95\% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.",

keywords = "Drug resistance, Levofloxacin, Moxifloxacin, Ofloxacin",

author = "Alvaro Schwalb and Rodrigo Cachay and Ericka Meza and Tatiana C{\'a}ceres and Amondrea Blackman and Fernanda Maruri and Sterling, \{Timothy R.\} and Eduardo Gotuzzo",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s13104-021-05832-0",

language = "Ingl{\'e}s",

volume = "14",

journal = "BMC Research Notes",

issn = "1756-0500",

number = "1",

}

TY - JOUR

T1 - Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru

AU - Schwalb, Alvaro

AU - Cachay, Rodrigo

AU - Meza, Ericka

AU - Cáceres, Tatiana

AU - Blackman, Amondrea

AU - Maruri, Fernanda

AU - Sterling, Timothy R.

AU - Gotuzzo, Eduardo

PY - 2021/12

Y1 - 2021/12

N2 - Objective: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. Results: There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.

AB - Objective: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. Results: There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.

KW - Drug resistance

KW - Levofloxacin

KW - Moxifloxacin

KW - Ofloxacin

UR - https://www.scopus.com/pages/publications/85119327370

U2 - 10.1186/s13104-021-05832-0

DO - 10.1186/s13104-021-05832-0

M3 - Artículo

C2 - 34776013

AN - SCOPUS:85119327370

SN - 1756-0500

VL - 14

JO - BMC Research Notes

JF - BMC Research Notes

IS - 1

M1 - 413

ER -

Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this